Levofloxacine Hikma (Levofloxacin)

Levofloxacin blocks bacterial DNA gyrase and topoisomerase IV, enzymes required for DNA replication and transcription. By preventing these enzymes from functioning, the drug halts bacterial cell division and leads to rapid bacterial death, providing bactericidal activity against a wide range of Gram‑negative and Gram‑positive organisms.

The specific dose of Levofloxacine Hikma is determined by the prescribing clinician based on the infection type, severity, patient weight, renal function, and other clinical factors. Healthcare professionals set the appropriate regimen and duration according to approved guidelines and individual patient needs.

Safety data for levofloxacin in pregnancy and lactation are limited. It is generally avoided unless the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To request Levofloxacine Hikma, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and necessary import documentation.

Levofloxacin offers broad‑spectrum coverage and convenient once‑daily dosing for many serious infections, often allowing intravenous-to‑oral switch. Compared with beta‑lactams, it may be more effective against resistant Gram‑negative organisms but carries specific risks such as tendon injury and QT prolongation. Choice depends on pathogen susceptibility, patient risk factors, and local resistance patterns.

Levofloxacine Hikma should be stored at ambient temperature, below 25 °C. Keep the product in its original container, protect it from moisture, direct sunlight, and extreme temperatures to maintain stability and potency.

Levofloxacine Hikma is supplied for intravenous infusion. The medication is diluted in an appropriate compatible solution and administered over a prescribed period, typically 30–60 minutes, under the supervision of qualified healthcare personnel.

Serious risks include tendon rupture (especially Achilles tendon), QT interval prolongation leading to arrhythmias, severe hypersensitivity reactions such as anaphylaxis or Stevens‑Johnson syndrome, and Clostridioides difficile‑associated diarrhea. Patients should be monitored closely for any signs of these events.

Levofloxacine Hikma is contraindicated in patients with a known hypersensitivity to levofloxacin or other fluoroquinolones. It should also be avoided in individuals with a history of tendon disorders related to fluoroquinolone use, uncontrolled epilepsy, or those taking medications that significantly prolong the QT interval without careful monitoring.